

Bruna Maria Roesler*

Center of Diagnosis of Digestive Diseases, School of Medical Sciences, State University of Campinas, Campinas, SP, Brazil

Dates: Received: 01 September, 2015; Accepted: 07 September, 2015; Published: 09 September, 2015

*Corresponding author: Brunna Maria Roesler, Center of Diagnosis of Digestive Diseases, School of Medical Sciences, State University of Campinas, Campinas, SP, Brazil, E-mail: roeslerbruna@gmail.com

www.peertechz.com

ISSN: 2455-2283

Editorial

Helicobacter pylori Infection and Hematologic Disorders: what do We Really Know?

The first description of *H. pylori* eradication reversing long-standing IDA was in 1997 [8] and since then several trials have reported that eradication of the microorganism could really resolve IDA [9-12], an important public health problem especially in developing countries. Despite of it, these studies present some limitations and their results were not corroborated with others, in which it was not found an important association between *H. pylori* eradication in the treatment of IDA [13,14].

Nevertheless, a meta-analysis of observational epidemiologic studies revealed an increased risk of IDA in *H. pylori* infected patients [15], and randomized controlled trials suggested that *H. pylori* eradication could improve iron absorption [16,17]. Two other meta-analysis of randomized control trials have supported this association [18,19]. In one of them it was demonstrated how the effect of *H. pylori* is more evident in patients with moderate to severe anemia compared with those with mild anemia [18]. In the other one it was suggested that *H. pylori* eradication therapy combined with iron administration seems to be more effective than iron administration alone for the treatment of IDA [19].

Considering these evidences, *H. pylori* is suggested to cause IDA by several mechanisms, including iron loss due to active hemorrhage secondary to gastritis, peptic ulcer disease or gastric cancer [20]; reduced iron absorption caused by pan gastritis [21]; and iron utilization for protein synthesis by the bacterium for colonization in the host environment [22]. In addition, *H. pylori* strains possessing virulence factors CagA and VacA have also been reported to participate in iron acquisition and colonization without damaging host tissue, being responsible for chronicity [23].

As we can conclude, *H. pylori* infection has been well studied in relation to IDA and some of the most important Consensus (Maastricht IV Consensus and Second Asia-Pacific Consensus) [24,25], on *H. pylori* as well as the British Society of Gastroenterology [26] have decided on their guidelines that testing and eradication of this bacterium have to be done in individuals with recurrent and unexplained IDA. Recently, the Guidelines for the management of *H. pylori* infection in Italy (The III Working Group Consensus Report 2015) considered that in patients with IDA *H. pylori* infection should be sought and treated [27]. Nevertheless, it would be important that larger sample randomized controlled trials were done in order to clarify the relationship between *H. pylori* infection and the small proportion of the contaminated subjects that develop such condition.

As regards to ITP, it is an autoimmune hematological condition in which destruction of the platelets is mediated by anti-platelet auto-

Editorial

One of the most important events on gastroenterology certainly was the isolation of *Helicobacter pylori* (*H. pylori*) by Barry Marshall and Robin Warren in 1983 [1], occurrence which redirected our understanding of the pathophysiology of gastrointestinal diseases. The production of urease as well as the mobility of these bacteria promoted by flagella were identified as essential factors for colonization of the gastric epithelium and, from there, within a few years, the list of *H. pylori* virulence factors for colonizing and persisting on the gastric surface epithelium besides some factors damaging the mucosa expanded greatly.

Nowadays, the association among *H. pylori* infection and chronic active gastritis, peptic ulcer disease, MALT lymphoma and gastric adenocarcinoma has been well established. Obviously, the outcome of the infection may involve a combination of bacterial, host and environmental factors, and despite the microorganism infects more than half of the world population, fewer than 20% of the infected individuals will develop symptoms from their infection [2,3].

Interestingly, in the last decade, several diseases from outside of the gastrointestinal tract have been associated with *H. pylori* infection. It has been suggested that it could be due to a variety of mechanisms that includes the production of a low-grade inflammatory state, the induction of molecular mimicry mechanisms by expressing proteins that mimic host peptides, and the interference with the absorbance of different nutrients and drugs [4,5].

The development of such hematologic disorders has been considered associated with *H. pylori* infection especially because this chronic infection is a condition in which autoimmunity is exalted. In addition, some virulence factors (especially CagA and VacA) appears to be involved in the outcome and progression of gastric (and possibly extra gastric) diseases [6], as well as the immune response to *H. pylori*, considering that both host's innate and adaptive immune system play a crucial role in the initiation and progression of this infection [7]. Thus, the most studied and discussed hematological disorders associated with *H. pylori* infection are iron deficiency-anemia (IDA) and idiopathic thrombocytopenic purpura (ITP).

antibodies in reticuloendothelial system [28]. The possible association between this disease and *H. pylori* infection was first described in 1998 [29] and since then several studies have been demonstrating that there is a consistent role in determining ITP played by this infection [30,31], especially in patients with mild thrombocytopenia [31].

In addition, important studies have demonstrated significant improvement in the platelet count after bacterium eradication in individuals with chronic ITP [32,33] as well as favorable platelet response in the patients in whom *H. pylori* was successfully eradicated [34,35]. Other important observation is that the absolute number of plasma cytoid dendritic cells, which is generally reduced in patients with ITP, is also reduced in patients with ITP and concomitant *H. pylori* infection; but it was observed that this number increased in those individuals after bacterium eradication, one important aspect if we consider the possible relationship between the infection and ITP development [36]. In contrast, one study suggested that the administration of macrolides in individuals with ITP may increase the platelet count independently from *H. pylori* infection, through an immunomodulatory effect intrinsic to the drug [37]. Another study reported a poor response to *H. pylori* eradication therapy in patients with chronic ITP in Western countries [38] and it was also reported that *H. pylori* eradication had no effect on the platelet count in individuals with ITP in Italy [39].

Concerning the pathogenic mechanisms, some hypothesis have been proposed to explain the possible association of *H. pylori* infection and ITP. The most plausible of them is the molecular mimicry [40], which is defined as similar structures shared by molecules from dissimilar genes or by their protein products [41]. For instance, it has been postulated that *H. pylori* surface antigen, such as CagA, evokes host systemic immune response that produces auto-antibodies with cross-react with host platelets [40,42]. Other researchers suggested that genetic influences could also be involved in the development of ITP in individuals infected with *H. pylori*. It was demonstrated that differences in HLA class II allele patterns between patients with ITP with or without *H. pylori* infection have been described and the presence of HLA-DQB1*03 pattern was associated with an increased probability of increase in platelet number in response to *H. pylori* infection [43].

Regarding to these findings and based on the significant positive platelet increase in patients with ITP in whose *H. pylori* was effectively done, it was also recommended by important Consensus, such as IV Maastricht Consensus and the Second Asia-Pacific Consensus Guidelines, that patients with ITP have to be submitted to *H. pylori* eradication therapy [24,25]. Despite of it, as well as in IDA, larger randomized controlled trials with long-term follow-up are still required before a firm conclusion can be drawn.

In conclusion, *H. pylori* infection has been associated with several extra digestive disorders and among them important emphasis has been attributed to IDA and ITP. If we consider strong scientific criteria, in these two conditions *H. pylori* infection can be really classified as a relevant factor of morbidity, aspect which has been demonstrated by several studies, especially meta-analysis. In 2005, the European Helicobacter Study Group, in the Third Maastricht Consensus Conference [44], defined for the first time eradication of

H. pylori in patients with extra intestinal diseases – IDA and ITP – based on the reversal of IDA and significant positive platelet increase in patients with ITP. Thereafter, we have been seeing several gradual changes in the recommendations for diagnosis and treatment of *H. pylori* infection, including the indication of the microorganism eradication in some gastrointestinal disorders. Future studies will surely point more extra digestive diseases possibly associated to *H. pylori* infection, highlighting our understanding about this ancient microorganism that has co-evolved with humans for over 60,000 years.

References

1. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1: 1311-1315.
2. Mishra S (2013) Is Helicobacter pylori good or bad? *Eur J Clin Microbiol Infect Dis* 32: 301-304.
3. Hagymási K, Tulassay Z (2014) Helicobacter pylori infection: New pathogenetic and clinical aspects. *World J Gastroenterol* 20: 6386-6399.
4. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G (2010) Extragastric manifestations of Helicobacter pylori infection. *Helicobacter* 15: 60-68.
5. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A (2014) Clinical effects of Helicobacter pylori outside the stomach. *Nat Rev Gastroenterol Hepatol* 11: 234-242.
6. Molnar B, Galamb O, Sipos F, Leiszter K, Tulassay Z (2010) Molecular pathogenesis of Helicobacter pylori infection: the role of bacterial virulence factors. *Dig Dis* 28: 604-608.
7. Ihan A, Pinchuk IV, Beswick EJ (2012) Inflammation, immunity, and vaccines for Helicobacter pylori infection. *Helicobacter* 17: 16-21.
8. Marignani M, Angeletti S, Bordini C, Malagnino F, Mancino C, et al. (1997) Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. *Scand J Gastroenterol* 32: 617-622.
9. Morita R, Hashino S, Okada K, Takahata M, Onozawa M, et al. (2009) Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura. *Rinsho Ketsueki* 50: 1655-1657.
10. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, et al. (2009) Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. *Korean J Gastroenterol* 54: 269-278.
11. van Hove A, Adang RP, van Kuijk WH (2009) [Unexplained iron-deficiency due to Helicobacter pylori]. *Ned Tijdschr Geneesk* 153: B350.
12. Duque X, Moran S, Mera R, Medina M, Martinez H, et al. (2010) Effect of eradication of Helicobacter pylori and iron deficiency supplementation on the iron status of children with iron deficiency. *Arch Med Res* 41: 38-45.
13. Qu XH, Huang XL, Xiong P, Zhu CY, Huang YL, et al. (2010) Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. *World J Gastroenterol* 16: 886-896.
14. Tan HJ, Goh KL (2012) Extragastric manifestations of Helicobacter pylori infection: facts or myth? A critical review. *J Dig Dis* 13: 342-349.
15. Muhsen K, Cohen D (2008) Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. *Helicobacter* 13: 323-340.
16. Valiyaveetil AN, Hamide A, Bobby Z, Krishnan R (2005) Effect of anti-Helicobacter pylori therapy on outcome of iron-deficiency anemia: a randomized, controlled study. *Indian J Gastroenterol* 24: 155-157.
17. Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX (2010) Effect of Helicobacter pylori eradication on iron deficiency. *Chin Med J (Engl)* 123: 1924-1930.

18. Yuan W, Li Yumin D, Yang L (2010) Iron deficiency anemia in *Helicobacter pylori* infection: meta-analysis of randomized controlled trials. *Scand J Gastroenterol* 45: 665-676.
19. Huang X, Qu X, Yan W, Huang Y, Cai M, et al. (2010) Iron deficiency anemia can be improved after eradication of *Helicobacter pylori*. *Postgrad Med J* 86: 272-278.
20. Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD (2013) The role of *Helicobacter pylori* infection in hematological disorders. *Eur J Intern Med* 24: 685-690.
21. Annibale B, Capurso G, Lahner E, Passi S, Ricci R, et al. (2003) Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with *Helicobacter pylori* gastritis and associated iron deficiency anemia. *Gut* 52: 496-501.
22. Realdi G, Dore MP, Fastame L (1999) Extradigestive manifestations of *Helicobacter pylori* infection: fact and fiction. *Dig Dis Sci* 44: 229-236.
23. Boyanova L (2011) Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. *Future Microbiol* 6: 843-846.
24. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, et al. (2009) Second Asia-Pacific Consensus Guidelines for *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 24: 1587-1600.
25. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, et al. (2012) Management of *Helicobacter pylori* infection – the Maastricht IV/Florence Consensus Report. *Gut* 61: 646-664.
26. Goddard AF, James MW, McIntyre AS, Scott BB (2011) Guidelines for the management of iron deficiency anemia. *Gut* 60: 1309-1316.
27. Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, et al. (2015) Guidelines for the management of *Helicobacter pylori* infection in Italy: The III Working Group Consensus Report 2015. *Dig Liver Dis* 2015 S1590-8658(15)00378-3.
28. Hershko C, Ianculovich M, Souroujon M (2007) A hematologist's view of unexplained iron deficiency anaemia in males: impact of *Helicobacter pylori* eradication. *Blood Cells Mol Dis* 38: 45-53.
29. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, et al. (1998) Regression of autoimmune thrombocytopenia after eradication of *Helicobacter pylori*. *Lancet* 352: 878.
30. Hasni SA (2012) Role of *Helicobacter pylori* infection in autoimmune diseases. *Curr Opin Rheumatol* 24: 429-434.
31. Payandeh M, Sohrabi N, Zare ME, Kansestani AN, Hashemian AIH (2012) Platelet count response to *Helicobacter pylori* eradication in Iranian patients with idiopathic thrombocytopenic purpura. *Mediterr J Hematol Infect Dis* 4: e20122056.
32. Emilia G, Longo G, Luppi M, Grandini G, Morselli M, et al. (2001) *Helicobacter pylori* eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. *Blood* 97: 812-814.
33. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, et al. (2005) Is eradication therapy useful as the first line of treatment in *Helicobacter pylori*-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. *Int J Hematol* 81: 162-168.
34. Sato R, Murakami K, Watanabe K, Okimoto T, Miyajima H, et al. (2004) Effect of *Helicobacter pylori* eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. *Arch Intern Med* 164: 1904-1907.
35. Inaba T, Mizuno M, Take S, Suwaki K, Honda T, et al. (2005) Eradication of *Helicobacter pylori* increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. *Eur J Clin Invest* 35: 214-219.
36. Saito A, Yokohama A, Osaki Y, Ogawa Y, Nakahashi H, et al. (2012) Circulating plasmacytoid dendritic cells in patients with primary and *Helicobacter pylori*-associated immune thrombocytopenia. *Eur J Haematol* 88: 340-349.
37. Ohe M, Hashino S (2011) Successful treatment with erythromycin for idiopathic thrombocytopenic purpura. *Korean J Haematol* 46: 139-142.
38. Ahn ER, Tiede MP, Jy W, Bidot CJ, Fontana V, et al. (2006) Platelet activation in *Helicobacter pylori*-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. *Acta Haematol* 116: 19-24.
39. Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, et al. (2005) *Helicobacter pylori* eradication in the management of patients with idiopathic thrombocytopenic purpura. *Am J Med* 118: 414-419.
40. Franceschi F, Christodoulides N, Kroll MH, Genta RM (2004) *Helicobacter pylori* and idiopathic thrombocytopenic purpura. *Ann Int Med* 140: 766-767.
41. Oldstone MBA (1989) Molecular mimicry as a mechanism for the cause and as a probe uncovering etiologic agent(s) of autoimmune disease. *Curr Top Microbiol Immunol* 145: 127-135.
42. Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, et al. (2004) Molecular mimicry by *Helicobacter pylori* CagA protein may be involved in the pathogenesis of *H. pylori*-associated chronic idiopathic thrombocytopenic purpura. *Br J Haematol* 124: 91-96.
43. Veneri D (2002) Idiopathic thrombocytopenic purpura, *Helicobacter pylori* infection, and HLA class II alleles. *Blood* 100: 1925-1926.
44. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E., et al. (2007) Current concepts on the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 56: 772-781.